Aerie Pharmaceuticals Inc. buy stratec
Start price
11.10.18
/
50%
€47.21
Target price
02.07.19
€72.16
Performance (%)
-48.50%
End price
02.07.19
€24.31
Summary
This prediction ended on 02.07.19 with a price of €24.31. The BUY prediction by stratec for Aerie Pharmaceuticals Inc. performed very badly with a performance of -48.50%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Aerie Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% | 65.510% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% | 95.368% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% | 42.232% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% | 59.132% |
Comments by stratec for this prediction
In the thread Aerie Pharmaceuticals Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
JMP Securities likes Aerie Pharmaceuticals (AERI) today as they reiterate their Buy rating and $80 price target. JMP's analyst believes Q3 revenue will hit $5.4 million, above the $4.8 million consensus. He also believes 'revenue and prescriptions to accelerate in 2019 when Aerie obtains extended Medicare Part D formulary coverage and Roclatan is approved'
(Vom Mitglied beendet)